A new mouse model may be critical for understanding the most aggressive types of pancreatic cancer and finding ways to prevent its growth and recurrence.
Studies exploring metformin’s power to prevent prostate cancer progression have been inconclusive. Columbia research now shows that the drug has promise, but only for specific patients.
Barbara Pro, MD, a leader in lymphoma research and care, has been named clinical director of the lymphoma program at Columbia University's Herbert Irving Comprehensive Cancer Center.
New Columbia research suggests that targeting neighboring bone cells may be a better strategy than targeting malignant stem cells to treat acute myeloid leukemia.
In the face of daunting disparities in health care, the medical community can take small steps that make a difference, a Columbia orthopedic surgeon writes.
By Christina Hernandez Sherwood | Portraits by Jörg Meyer
December 23, 2021
The National Cancer Act, signed into law Dec. 23, 1971, funded the expansion of cancer research and care at Columbia. Today, with plans for a new clinical building, the future looks bright.
Innovation and discovery are at the heart of Herbert Irving Comprehensive Cancer Center's mission to reduce the burden of cancer. Learn more in the HICCC's 2021 annual report.
The new center will build upon the dedicated MDS program at Columbia University, a longstanding program of excellence that has served as a national leader in MDS research.
The latest advance in radiation therapy—using AI to adjust treatments as needed—is now available for select cancer patients at Columbia University Irving Medical Center/NewYork-Presbyterian.